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Summary 
Previous experiments from this laboratory have shown that Lewis rats were protected from ex- 
perimental allergic encephalomyelitis (EAE) induced by the injection of myelin basic protein (MBP) 
in Freund's complete adjuvant if they were treated with the encephalitogenic peptide of MBP 
covalently linked to mouse anti-rat immunoglobulin (Ig) D. It was suggested that this protec- 
tion developed because the antibody-peptide conjugate targeted the peptide to B cells and that 
this mode of presentation induced a Th2-1ike T  cell response that controlled the concomitant 
encephalitogenic Thl reaction to the autoantigen.  The current experiments were carried out 
to test this hypothesis and to examine the alternative explanation for the protective effect of 
the conjugate pretreatment, namely that it induced a state of nonresponsiveness in the autoanti- 
genspecific T  cells. It was shown that EAE induction was suppressed in Lewis rats when the 
antibody-peptide conjugate was injected intravenously 14 and 7 d before immunization with 
MBP in adjuvant, but that anti-MBP antibody titers were at least as high in these animals as 
in controls that were not pretreated with the conjugate before immunization. Lymph node cells 
from these pretreated animals, while proliferating in vitro to MBP as vigorously as those from 
controls, produced less interferon 3'  and were very inferior in their ability to transfer disease 
after this in vitro activation. In contrast, these same lymph node cells from protected rats gener- 
ated markedly increased levels of messenger RNA for interleukin (IL)-4 and IL-13. When these 
in vitro experiments were repeated using the encephalitogenic peptide rather than MBP as the 
stimulus, the proliferative response of lymph node cells from pretreated donors was less than 
that from controls but was still readily detectable in the majority of experiments. Furthermore, 
the cytokine expression induced by the peptide was similar to that elicited by whole MBP. While 
these results support the original hypothesis that the anti-IgD-peptide conjugate pretreatment 
protected rats from EAE by inducing a Th2-type cytokine response, a totally unexpected finding 
was that this pretreatment greatly reduced the level of leukocyte infiltration into the central nervous 
system. This result provides a direct explanation for the protective effect of the pretreatment, 
but it raises questions regarding migratory and homing patterns of leukocytes activated by different 
immunological stimuli. 
E 
xperimental allergic encephalomyelitis  (EAE)  1 is a T cell- 
dependent, paralytic autoimmune disease that can be in- 
duced in experimental animals by the injection of myelin- 
derived autoantigens emulsified in CFA. In Lewis rats, which 
I Abbreviations used in this  paper: CNS, central nervous system;  EAE, ex- 
perimental  allergic  encephalomyelitis;  MBP, myelin  basic protein; R.T-PCR,, 
reverse transcription PCk. 
are a particularly susceptible strain,  active EAE can be in- 
duced either by immunization with guinea pig myelin basic 
protein (MBP) or with a peptide consisting of amino acid 
residues 70-86 of the mature protein sequence (1, 2).  The 
disease can also be transferred (passive EAE) from animals 
with active EAE to naive syngeneic recipients by the intrave- 
nous injection of donor spleen or lymph node cells after their 
in vitro culture with MBP. 
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the  action  of CD4 +  T  lymphocytes that  produce  focal 
edema in the central nervous system (CNS)  (3,  4), but in 
both active and passive EAE, the disease is transient and affected 
animals recover completely within 4-5 d of its onset (5). At- 
tempts to induce further episodes  of the disease are unsuc- 
cessful despite the fact that spleen cells from recovered animals 
have the potential to cause the disease.  It appears  that the 
pathological response to guinea pig MBP is somehow held 
in check in animals that have recovered from their single epi- 
sode of paralysis. 
Previous experiments carried out in this laboratory reported 
that rats treated with the encephalitogenic peptide of MBP 
covalently coupled to monoclonal anti-IgD antibody were 
resistant to the induction of EAE on concomitant challenge 
with MBP in  CFA  (6).  This  resistance  was provisionally 
ascribed to the fact that the antibody-peptide conjugate tar- 
geted the autoantigen to B cells and that the presentation 
of the peptide by these cells would be expected to induce 
a Th2-1ike cytokine response (7-9). Given that Th2 cytokines 
antagonize Thl responses  (10-13)  and that EAE is a Thl 
cell-mediated disease (14-16),  targeting the peptide in this 
way is expected to have the observed effect. It has also been 
shown, however, that when B cells are used to present mono- 
meric antigen to T cells, the latter fail to respond to a subse- 
quent challenge with the same antigen in adjuvant (17, 18). 
The ability of B cells to induce T cell tolerance in this system 
depends on the B cells remaining in a nonactivated state (17, 
18), but the level of activation of the B cells in our earlier 
experiments was not determined. Consequently, an alterna- 
tive explanation for the capacity of the antibody-peptide con- 
jugate to prevent EAE was that it induced a state of non- 
responsiveness  in peptide-specific  T  cells. 
The antibody-peptide treatment in these experiments was 
started at the same time as the challenge with MBP in CFA 
so that, in principle, some T cells might have been activated 
without  first  encountering  the  encephalitogenic  peptide 
presented on B cells. It was anticipated that this possibility 
could cause difficulties in interpreting experiments designed 
to identify the mechanism of disease resistance,  so for the 
present study, the protocol was modified. In the experiments 
now reported, the anti-IgD-peptide conjugate injections were 
given well before the challenge with MBP in CFA, thereby 
favoring previous antigen presentation by B cells. It was found 
that this mode of preimmunization also prevented the subse- 
quent induction of EAE. The mechanism of this refractori- 
ness was then studied; particularly, experiments were carried 
out to determine whether it was a result of T cell nonrespon- 
siveness or of an induced change in the cytokine response 
to the encephalitogen. 
Materials and Methods 
Animals and Induction of EAE.  8-12-wk-old  Lewis strain rats 
of  either sex were used and bred in the specific  pathogen-free (SPF) 
unit of the Medical Research Council Cellular Immunology Unit 
(Oxford, UK). To induce active EAE, animals  were injected in the 
hind footpads with 50/zg MBP in CFA (19). In individual experi- 
ments all animals were of the same sex. 
Passive EAE was adoptively  transferred  from immunized donors 
to naive recipients as described (20). Briefly, splenocytes  or lymph 
node cells (popliteal, mesenteric, and paraaortic) from rats im- 
munized with MBP in CFA were stimulated in vitro for 3 d with 
MBP and then injected  intravenously  into syngeneic  recipients. The 
cell doses used for transfer were between 3-5  x  107 viable leuko- 
cytes. Animals were scored daily for clinical signs of disease on a 
scale from 0 to 5 depending on severity: 0, normal; 1, limp tail; 
2, hind limb weakness; 3, unilateral  hind limb paralysis;  4, bilateral 
hind limb paralysis; and 5, bilateral hind limb paralysis and incon- 
tinence. 
mAbs and the Preparation of Antibody--Peptide Conjugates.  The 
mAbs used in these studies were as follows:  W3/25 (anti-rat CD4) 
(21), OX-6 (anti-rat  MHC class II) (22), OX-8 (anti-rat  CD8) 
(23), OX-21 (anti-human C3b inactivator)  (24), ED1 (anti-rat mac- 
rophage) (25), OX60 (anti-rat IgD) (6), and OX81 (a neutralizing 
anti-rat II~4 mAb [Ramirez F., D. Fowell, M. Puklavec, S. Sim- 
monds, and D. Mason, manuscript submitted for publication]). 
The mAbs OX60 and OX81 are mouse IgG1 Igs, and they were 
prepared from ascitic fluid by sodium sulphate precipitation and 
ion exchange chromatography. OX60 mAb and OVA were indi- 
vidually covalently  linked to the encephalitogenic  peptide of MBP 
by sulpho-SMCC reagent (Pierce Chemical Co., Rockford, IL). 
The encephalitogenic peptide (1) was synthesized by the Fmoc 
HOBt/NMP method (26), but with a Cys residue added to its 
NH2 terminus to facilitate  coupling by the sulpho-SMCC reagent 
(full sequence: CGSLPQKSQRSQDENPVV). Rats were injected 
i.v. with purified mouse anti-rat IL-4 mAb (OX81) according to 
the schedule set out in results. 
Proliferative Responses.  Lymph node cells or splenocytes  were 
stimulated with 20 #g/ml MBP, 2/zg/ml of the encephalitogenic 
peptide, or 5 #g/ml Con A in RPMI/10% FCS containing 2  x 
10 -5 M 2-ME, 1 mM sodium pyruvate plus antibiotics. Prolifera- 
tion was measured by 3[H]thymidine uptake during the last 18 h 
of a 72-h culture period and results expressed as mean cpm of qua- 
druplicate wells. At various times throughout the culture, super- 
natants were removed  for cytokine analysis  and cells were harvested 
after 24 or 48 h stimulation and RNA purified for analysis of 
cytokine gene expression by reverse transcription PCR (RT-PCR; 
see below). 
Cytokine Assays.  Culture supematants were assayed  for the pres- 
ence of IIr  using the murine IL-2-dependent cell line (CTLL) as 
previously  described (27). Briefly,  different  volumes  of samples were 
added to 2  x  104 CTLL cells (final concentration was between 
5 and 50%) and incubated for 18 h at 37~  The cells were then 
pulsed with 0.5/xCi of 3[H]thymidine for 6 h and the incorpora- 
tion of radiolabel was measured. Values are expressed as units per 
milliliter of  IL-2, as derived  from a standard  curve  constructed using 
a commercial  preparation of recombinant human IL-2 (Boehringer 
Mannheim GmbH, Mannheim, Germany). 
IFN-3, protein in the supematant was measured  by specific  ELISA. 
96-well plates were coated overnight at 4~  with 10 t~g/ml of an 
anti-rat IFN-'y mAb (DB1) and blocked for 30 min with 1% BSA 
in PBS. Undiluted tissue culture supernatant (50 #1 per well), fol- 
lowed by rabbit anti-mouse IFN-3' antiserum that cross-reacts with 
rat IFN-v (diluted 1/200) and swine anti-rabbit IgG-alkaline  phos- 
phatase-conjugated antiserum diluted 1/1,000 (Dako, Glostrup, 
Denmark), were sequentially incubated for 2 h at room tempera- 
ture, separated  by three washes with PBS containing 0.05% Tween 
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phenyl phosphate (Sigma  Chemical Co., St. Louis,  MO) at 5 mg/ml 
for 30 rain at room temperature before measuring the absorbance 
at 405 nm. Values are expressed as U/ml IFN-3, derived from a 
standard curve constructed using rat recombinant IFN-% The DB1 
mAb and recombinant rat IFN-'y were kindly supplied by Dr. P. 
Van der Meide (TNO,  Rijswijk,  The Netherlands). The rabbit 
anti-mouse IFN-3~ antiserum was kindly provided by Dr. J. Tite 
(Wellcome Research Laboratories, Beckenham, UK). 
RT-PCR.  Total  cellular RNA  was  isolated from  5  x  106 
stimulated or unstimulated lymphocytes using RNAzol B (Bio- 
genesis, Poole, UK). RNA was reverse transcribed to cDNA using 
oligo-dT as primer and MMLV  reverse transcriptase (GIBCO BRL, 
Paisley, Scotland) in a final volume of 40 #1 as described (28). For 
semiquantitative PCR analysis  of cytokine mRNA levels, serial  di- 
lutions of the cDNA were amplified  in 50-#1 reaction volumes as 
described (28). Reactions were performed in an MJ Research, Inc. 
programmable thermal controller (Genetic Research Instrumenta- 
tion Ltd., Dunmow, UK) for the indicated number of cycles. Each 
cycle consisted of 93~  for 1 min, 60~  for 2 min, and 72~  for 
3 rain using 37 cycles  for I1.-4 and IL-13 and 23 cycles for/~-actin. 
After amplification, 10 #1 of amplified  product was then separated 
by electrophoresis on 1.5% agarose minigels and visualized by 
ethidium bromide staining. 
Primers used were as follows:  ~-actin sense  primer 5'-ATG CCA 
TCC TGC GTC TGG ACC TGG C-Y, B-actin antisense primer 
5'-AGC ATT TGC GGT GCA CGA TGG C-Y, IL-4 sense primer 
5'-TGA TGG GTC TCA GCC CCC ACC TTG C-3', IL-4 an- 
tisense primer 5'-CTT TCA GTG TTG TGA GCG TGG ACT 
C-Y (28); IL-13 sense primer 5'-CAG GGA GCT TAT CGA GGA 
GC-Y, and IL-13 antisense primer 5'-CGA GTT AGT AGG ACT 
TTT GAA G-Y (29). These primers were designed to amplify 
cDNA fragments, representing mature 607-bp mRNA transcripts 
for/~-actin, 378 bp for IL-4 cDNA, and 279 bp for IL-13 cDNA. 
MBP Antibody Detection.  Sera  from immunized rats were ob- 
tained by centrifugation of blood samples that were collected by 
bleeding rats from the tail artery under halothane anesthesia. 
For detection of  MBP-specific  antibodies, a standard ELISA  tech- 
nique was applied. Briefly,  ELISA  plates were coated  overnight with 
10/~g/ml of purified MBP at 4~  After saturation with 5% milk 
powder for 90 rain, the plates were washed and serum samples were 
added in different dilutions (between 1:5  x  102 and 1:5  x  104). 
After a 2-h incubation period, plates were extensively  washed and 
MBpospecific antibodies were detected by addition of horseradish 
peroxidase-conjugated rabbit anti-rat IgG diluted in 5% normal 
mouse serum (Serotec, Kidlington, UK). Substrate was added and 
color development  was assayed  in an ELISA  plate reader. Each serum 
was tested in duplicate. Results were expressed as OD at 492 nm. 
Antibodies to mouse IgG were assayed  in essentially the same 
way as those to MBP, except that the ELISA plates were coated 
with 10/zg/ml of OX60 IgG and the sera were diluted to 1:500. 
Immunohistology.  Cryostat sections of rat spinal cord (5 #m) 
were prepared from rats 15 d after immunization with MBP. They 
were air-dried and stained using the immunoperoxidase method 
(30). Briefly,  sections were fixed in ethanol, washed, and incubated 
with the chosen mAb for 1 h at 4~  After further washes, the 
slides were incubated with peroxidase-labeled rabbit anti-mouse 
Ig (Dakopatts Ltd., Copenhagen, Denmark). After further washes, 
bound antibody was revealed using 3, 3' diaminobenzidine HC1. 
Infiltrating CD4 § T cells were detected using the mAb W3/25, 
macrophages by their reactivity with the mAb ED-1, and MHC 
class II antigen with mAb OX6. 
Resul~ 
Pretreatment with Anti-IgD-Peptide Conjugate Protects Rats 
from Active EAE.  Lewis rats were injected i.v. with 100 #g 
of mouse anti-rat IgD mAb conjugated to the encephalito- 
genic peptide of MBP (OX60-pep) on days - 14 and - 7 and 
were challenged subcutaneously with MBP in CFA on day 
0 (OX60-pep  group).  The control rats received either 100 
#g of OX60 mAb alone (OX60 group), a mixture of 100 
/zg of OX60 mAb and 2 #g of encephalitogenic peptide of 
MBP (OX60 +pep group), the encephalitogenic peptide cou- 
pled to OVA (OVA-pep group), or PBS only (PBS group). 
As Table 1 shows,  pretreatment with the OX60+pep con- 
jugate strongly suppressed  disease:  16 out of the 20 Lewis 
rats pretreated with OX60-pep and challenged with MBP 
in CFA were completely protected from EAE (Table 1, row 
1 ),  and the remaining four rats developed  a late and mild 
form of the disease. In contrast, 10-14 d after challenge, all 
the control rats in all the treatment control groups (PBS, 
OX60, OX60+ pep, and OVA-pep) exhibited severe EAE and 
recovered. 
These data are consistent with those already published (6) 
in that they show that targeting of the encephalitogenic pep- 
tide of MBP to B cells by chemically linking the peptide to 
an  anti-IgD  mAb  prevents  the  induction  of EAE  after 
challenging the animals with MBP. 
Lymph Node Cells but not Spleen Cells  from Protected Rats 
Proliferate to MBP and ConA.  Two rats were injected with 
100 #g of OX60-pep on days  - 14 and  - 7, and were chal- 
lenged with MBP on day 0. Two control rats were injected 
with PBS instead of OX60-pep.  11 or 15 d after MBP chal- 
lenge, splenocytes and cells from pooled draining lymph nodes 
were placed in culture and stimulated with MBP, with the 
encephalitogenic peptide of MBP or with ConA. The ex- 
periment was repeated six more times. 
Fig. 1 shows the results of one representative experiment. 
Proliferation to MBP (Fig.  1 C) and ConA (Fig.  1 D) of 
lymph node cells from protected rats was equal to that of 
lymph node cells from control rats.  In contrast, spleen cells 
from protected rats mounted a reduced proliferative response 
to MBP (Fig.  1 A) and ConA (Fig.  1 B). This reduction 
of the proliferative response  was  never  observed in  PBS- 
pretreated rats in the seven independent experiments, but it 
was found in five out of the seven experiments in OX60- 
pep-pretreated animals.  The proliferative response was not 
restored by increasing the concentration of MBP to 100 #g/ml 
or by adding exogenous I/:2 (data not shown). This same 
nonresponsiveness of splenocytes was found in animals that 
received, as pretreatment, a mixture of peptide and anti-IgD 
mAb (data not shown). As noted in the preceding section, 
the recipients of this antibody-peptide mixture developed EAE 
with the same severity as controls (Table 1), indicating that 
this nonresponsiveness was not necessarily  associated  with 
protection from EAE. 
When lymphocytes  from the draining lymph nodes of  rats 
challenged with MBP in CFA after anti-IgD-peptide pretreat- 
ment were stimulated in vitro with the encephalitogenic pep- 
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Clinical  score*  Mean duration 
Group  Incidence  (%)  Day of onset*  mean (range)  (d) 
OX60-pepS  4/20  (20)  15.2  +  0.9511  0.3  (0-2)  3.0  +  1.1511 
PBS s  21/21  (100)  12.1  _+  0.90  4.3  (3-5)  4.6  _+  0.97 
OX60  5/5  (100)  11.8  _+  1.09  4.2  (3-4)  4.6  _+ 0.54 
OX60  +  pep  5/5  (100)  12.6  _+  0.89  3.6  (1-4)  4.2  _+  0.44 
OVA-pep  4/4  (100)  12.5  +  0.57  3.5  (1-5)  4.3  _+  0.44 
* Mean number  _+ SE of days between  MBP immunization  and onset of clinical EAE. 
Mean grade of clinical EAE at the time of maximum intensity of inflammation for all rats in the group. 
g Rats from six independent experiments. 
II Data refer to the four rats in this group that  developed detectable signs of EAE. 
tide rather  than  with  whole  MBP,  the  results  were rather 
different to those illustrated in Fig.  1. Proliferative responses 
from  the  lymph nodes  of pretreated  rats  were  usually but 
not always less than those from control donors (stimulation 
index  --  1.37  +  0.32 in protected rats vs 2.1  _+  0.87 in dis- 
eased rats).  The level of reduced reactivity was highly vari- 
able,  but  this  variation  did  not  correlate with  the  level of 
protection from EAE, which was almost complete in all ex- 
periments.  The origin of this variability is not apparent.  In 
no case did splenocytes from anti-IgD-peptide pretreated rats 
proliferate in  vitro  to  the  encephalitogenic  peptide. 
Lymph Node Cells and Splenocytes from Protected Rats Have 
a Diminished  Capacity to  Transfer EAE.  As  shown  in Fig. 
2, severe EAE developed in all 10 naive Lewis rats given 3-5 
x  107 MBP-stimulated  lymph node cells (Fig.  2, A  and B, 
four recipients) or spleen cells (Fig. 2, C and D, six recipients) 
from rats pretreated with PBS and challenged with MBP (PBS 
group).  Paralysis appeared, as expected,  5 or 6 d  after adop- 
tive transfer.  In contrast,  naive Lewis rats receiving 3-5  x 
107 MBP-stimulated lymph node cells (Fig. 2, A  and B, four 
recipients)  or  spleen cells (Fig.  2,  C  and D,  six recipients) 
from protected rats (OX60-pep group) developed a mild form 
of the disease that appeared later than in the controls.  The 
data are from two independent  experiments (Fig.  2, A  and 
C,  and B  and D).  This  reduced  ability of cells from pro- 
tected rats to transfer EAE could not be explained by a general 
hyporesponsiveness to the autoantigen because lymph node 
cells from these animals proliferated  as well to MBP as did 
those  from controls  (Fig.  1  C). 
Lymph Node Cells and Splenocytes from Protected Rats Pro- 
duce Less IFN-%  On day 11 after immunization with MBP, 
lymph node cells and splenocytes from protected and diseased 
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Figure  1.  Effect  of OX60-pep pretreatment on the 
proliferative  response to MBP and to ConA. Spleens and 
lymph nodes from four Lewis rats challenged with MBP 
after being pretreated with OX60-pep (filled  squares, two 
rats) or PBS (open squares, two rats) on days -14 and 
-7 were removed 11 d after MBP challenge. Spleno- 
cytes (A and B) or lymph node cells (C and D) were 
cultured, at several concentrations, in the presence of 
20/~g/ml MBP (.4 and C) or 5 pg/ml ConA (B and 
D). Proliferation was assessed with a 18-h 3[H]thymi- 
dine (0.5/~Ci)  pulse added after 48 h of stimulation. 
Results of one representative experiment out of five are 
shown and expressed  as cpm + SE of quadruplicate mea- 
surements. 
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Figure  2.  Effect  of OX60-pep pretreatment on adoptive transfer of EAE. 
The figure shows the adoptive transfer of EAE with lymph node cells (A 
and B) or splenocytes  (C and D) from animals where EAE was completely 
suppressed by anti-IgD-pepride pretreatment (filled squares) or from con- 
trol diseased rats (open  squares), where PBS was used instead of anti-IgD-pep- 
tide. Animals pretreated with PBS or anti-IgD-peptide  14 and 7 d before 
MBP challenge were killed on day 11 or 13 after this challenge and lymph 
node and spleen cells were prepared. The cells were cultured in vitro with 
MBP  (2  #g/ml)  and  3-5  x  107 viable leukocytes were injected in- 
traperitoneally into each naive syngeneic recipient. The results shown are 
of two independent experiments (two rats in each experiment for lymph 
node cells; three rats in each experiment for splenocytes) and represent 
the mean clinical scores for paralysis. 
rats were stimulated with the autoantigen MBP. Culture su- 
pernatants  were removed at 24 and 48 h,  and were assayed 
for IL-2 and  IFN-3'. 
As shown  in Fig.  3,  the  amount  of IL-2 detected  in the 
supernatants from MBP-stimulated pooled lymph node cells 
(Fig. 3 A) or splenocytes (Fig. 3 B) obtained from two OX60- 
pep-pretreated animals did not differ from what was detected 
in the supernatants from the corresponding lymphocytes of 
two control PBS pretreated rats. In contrast,  the amount of 
IFN-3' produced by MBP-stimulated lymph node cells (Fig. 
4 A) or splenocytes (Fig.  4 B) from protected rats was very 
reduced  compared to  that  produced  by cells from diseased 
rats. In no instance did unstimulated cells produce either IL-2 
or  IFN-3~  (not  shown).  Two  additional  experiments  gave 
similar  results. 
Lymph Node and Spleen  Cells from Protected Rats Express 
Elevated Levels of mRNA for 11-,4 and IL13.  Experiments were 
carried  out  to  determine  the  effects of pretreatment  with 
OX60-pep on mKNA levels for IL-4 and IL-13 using a semi- 
quantitative  RT-PCR technique  (28).  On  day  11  after im- 
munization with MBP, lymph node cells from protected rats 
(OX60-pep-pretreated rats), after 24 h stimulation with MBP, 
expressed higher levels of IL-4 (~5x)  and IL-13 (~,10x)  in 
comparison to those expressed by MBP-stimulated lymph node 
cells from diseased rats (Fig.  5).  The/~-actin mRNA  levels 
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Figure  3.  Ib2 production by MBP-stimulated lymph node and spleen 
cells from OX60-pep-pretreated rats and from controls. Spleens and lymph 
nodes from four Lewis rats immunized with MBP after being pretreated 
with OX60-pep (solid bars, two rats) or PBS (open bars, two rats) on days 
-14 and  -7 were removed 11 d after MBP challenge. Splenocytes (A) 
or lymph node cells (B) were stimulated at 5  x  l0  s cells per well with 
20 #g/ml of MBP. Supernatants were collected after 24 and 48 h stimula- 
tion and were analyzed for the presence of IL-2 protein by using the CTLL 
bioassay. Results of one representative experiment out of three are shown 
and expressed  as units per milliliter. All values represent the mean of duplicate 
determination;  the range was within  10-15% of the mean. 
were similar in both groups.  Similar results  were obtained 
when the encephalitogenic peptide was used as stimulus rather 
than  MBP  (data  not  shown). 
A  Neutralizing  Anti-Rat II.r4 mAb Impairs the Protection In- 
duced by Pretreatment with Anti-IgD-Peptide.  Experiments 
were carried out to determine the role of IL-4 in preventing 
EAE  induction  by  anti-IgD-peptide  pretreatment.  Rats 
pretreated with PBS or OX60-pep as described elsewhere (Table 
1) were injected with 5 mg of neutralizing anti-rat I[,4 mAb 
IgG (OX81) on day  -  14 and thereafter with 3 mg of OX81 
mAb on alternate days until day 0, the day of immunization 
with MBP.  As Table 2  shows,  the control injections  (rows 
I  and 2)  had  no  effect on  the  severity of disease while,  as 
expected, the pretreatment with OX60-pep prevented the de- 
velopment of EAE. In contrast, the anti-IL-4 mAb injections 
diminished  the  protection  induced  by OX60-pep  pretreat- 
ment. Six out of the seven rats in this group developed EAE. 
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Figure  4.  Comparison  oflFN-'y production  by MBP-stimulated  lymph 
node and spleen  cells from OX60-pep- or PBS-pretreated  rats. The same 
supernatants as those  tested  for II~2  in Fig. 3 were also assayed  for IFN-'y. 
Data for the lymph  node  cells  are shown  in (.4) and for splenocyte  cultures 
in (B). Solid  bars refer  to supernatants from anti-IgD-peptide-pretreated 
rats and open bars to the controls. Supernatants were collected  after 24 
and 48 h of stimulation and analyzed  for the presence  of IFN-'y  protein 
by specific  ELISA. Results of one representative  experiment  out of three 
are shown and expressed as units per milliliter. All values represent the 
mean of  duplicate  determination;  the range  was within 5-15% of  the mean. 
other protected rats showed the same result. As recorded in 
Table 1, a small proportion of protected rats developed a very 
mild form of EAE that was presumably associated  with a 
degree of leukocyte infiltration.  Nevertheless, it is evident 
that the protection from EAE afforded by the anti-IgD-pep- 
tide pretreatment was associated with a much diminished level 
of encephalomyelitis as evaluated histologically. 
Rats Protected  from EAE by Anti-IgD-Peptide Pretreatment 
Make Undiminished  Antibody Responses to MBP.  The anti- 
body response to MBP in the OX60-pep-pretreated group 
was assayed on day 11  (Fig.  7 A,  five rats) and on day 21 
(Fig.  7 B, five rats) after challenge with MBP in CFA and 
compared with  that  from the corresponding controls.  As 
shown, animals from the OX60-pep group had antibody levels 
at least as high as those from controls with EAE. 
The same sera were assayed for antibodies to OX60 mAb. 
Of the 10 anti-IgD-peptide-pretreated rats examined, one 
made a detectable response (day 21) but the results from the 
remaining nine were indistinguishable from those obtained 
from control rats pretreated with  PBS (data not shown). 
Discussion 
The data presented are consistent with those already pub- 
lished (6) in that they show that targeting of the encephalito- 
genic peptide of MBP to B cells by chemically linking it to 
an anti-IgD mAb prevents the induction of EAE after chal- 
lenge of the experimental animals with MBP in CFA (Table 
1). As indicated in the Introduction, the aim of this study 
was to distinguish between two possible alternative explana- 
Among these six rats, two developed severe disease (bilateral 
hind limb paralysis,  grade 4) comparable to that observed in 
the control group,  and  the remaining rats developed mild 
disease.  The effect of the  anti-IL-4  mAb  was  statistically 
significant  (P <0.029 by Fisher's exact test). In contrast, when 
an irrelevant antibody (OX21) was used in place of OX81, 
no abrogation of protection was  observed (Table 2). 
Rats Protected  from EAE by Anti-IgD-Peptide Pretreatment 
Have Few Infiltrating  Leukocytes  in Their Spinal Cords.  Immu- 
nohistological examination of the spinal cords of anti-IgD- 
peptide-pretreated and control rats 15 d after challenge with 
MBP in CFA showed a very marked reduction in the magni- 
tude of the leukocyte infiltrate in the protected animals. This 
reduction was  observed for CD4 §  and CD8 §  T  cells  and 
for macrophages, and there was a parallel reduction of MHC 
class II antigen expression on the microglia.  Fig.  6  shows 
an example in which leukocyte infiltration and MHC antigen 
class II expression were observed in diseased rats but not in 
protected rats. Three other randomly selected samples from 
Figure  5.  IL-4  and IL-13  mRNA expression  by MBP-stimulated  lymph 
node cells from OX60-pep-pretreated  rats and from controls. The figure 
shows mRNA expression  by lymph node cells removed  11 d after MBP 
challenge  and stimulated  with MBP for 24 h. (Lanes  I-5) Amplified  prod- 
ucts from increasing threefold  dilutions of cDNA from MBP-stimulated 
lymph node cells from protected  rats (OX60-pep-pretreated  rats). (Lanes 
6-10) Dilutions of cDNA from MBP-stimulated diseased rats (PBS- 
pretreated control  rats). (Lane  11 ) A negative  control  (all buffers  without 
RNA). The cDNA templates  ranged  from  3/xl of  undiluted  cDNA (lanes 
I and 6) to 3/xl of 1/81 dilutions (lanes 5 and 10). Hinfl-digested  pATx 
is the molecular  weight marker, The cDNA for IL-4  and IL-13  was exam- 
ined after  37 amplification  cycles  and cDNA  for/~-actin  after  23 amplification 
cycles. Results of one representative  experiment  out of two are shown. 
340  Cytokines  and T Cell Migration in the Pathogenesis of EAE Table 2.  Incidence  of EAE in  OX60-pep-pretreated Rats and Controls Treated with 0X81  (Anti-Rat IL-4) 
Clinical  score*  Mean duration 
Group  Incidence (%)  Day of onset*  mean  (range)  (d) 
PBS  s  14/14  (100)  12.2  _+  0.9  3.3  (0.5-5)  4.0  _+  0.9 
PBS  +  Ox81U  3/3  (100)  11.7  _+  0.6  4.0 (4)  7.0  _+  3.5 
OX60-pepS  4/13  (31)  17.0  _+  3.5  0.5  (0-4)  3.2  _+  1.7 
OX60-pep  +  OX21  2/5  (40)  15.0  _+  1.4  0.4  (0-1)  4.0  _+  1.4 
OX60-pep  +  OX8111  6/7  (86)  15.0  _+  2.6  1.6  (0-4)  5.0  _+  2.6 
* Mean number _+  SE of days between MBP immunization and onset of clinical EAE. Data refer only to the rats that developed detectable signs of EAE. 
Mean grade of clinical EAE at the time of maximum paralysis for all rats in the group. 
Rats from three independent experiments. 
II Rats from two independent experiments. 
tions for the observed protective effect of the anti-IgD-pep- 
tide conjugate,  namely the induction of T  cell nonrespon- 
siveness or the modification of the cytokine repertoire to the 
encephalitogen. 
It was found that  the anti-IgD-peptide pretreatment  es- 
sentiaUy abrogated the leukocyte infiltration into the CNS. 
Since EAE is a cell-mediated disease,  this observation provided 
a simple explanation for the protective effect of the conjugate 
but raises the question as to its cause. This lack of infiltration 
could,  in principle,  have arisen because  the potentially  en- 
Figure  6.  Immunohistological staining of spinal cords from rats with EAE and from those protected  by pretreatment with anti-IgD-peptide. Shown 
are cryostat sections of spinal cord from Lewis rats challenged with MBP after being pretreated with PBS (A-C) or with OX60-pep (D). The sections 
are stained for CD4 + T cells (A), for macrophages (B), and for MHC class II antigen (C and D).  x400. 
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Figure  7.  MBP-specific  antibody  production by OX60-pep-pretreated 
rats and by controls. Sera from animals of both experimental groups (filled 
circles, OX60-pep-pretreated rats; open circles, PBS-pretreated rats) were 
tested for anti-MBP autoantibody  production. The rats were bled on day 
11 (A, n = 5 for each group) and on day 21 (B, n = 5 for each group) 
after challenge with MBP. Data are represented as absorbance  values for 
individual rats. All values represent the mean of duplicate determination; 
the range was within 5-10% of the mean. 
cephalitogenic T  cells  had been rendered nonresponsive by 
their exposure to the anti-IgD-peptide  reagent  or because 
the migratory patterns and inflammatory potential of the reac- 
tive cells  were changed  by the conjugate. 
With regard to the possible induction of T cell nonrespon- 
siveness  in our experiments,  it has been shown  that  poly- 
clonal monomeric antigen,  injected in vivo in the form of 
Fab anti-IgD, induces nonresponsiveness in those T cells that 
are specific for the xenogeneic immunoglobulin determinants 
expressed on the Fab fragments of the anti-IgD antibody (17, 
18). Use of Fab fragments in these experiments ensured that 
the surface Ig on the B cells, to which the anti-IgD bound, 
was not cross-linked, so that these cells remained in an inac- 
tivated state. In contrast, the use of polyclonal or monoclonal 
F(ab')2  anti-IgD  fragments  in  similar  experiments  did not 
lead to nonresponsiveness,  a result ascribed to the fact that 
the bivalent F(ab')2 molecules were able to cross-link surface 
Ig on the B cells and thereby activate them (17,  18). More 
recent results have modified this conclusion by demonstrating 
that the outcome of such experiments depends on the dose 
of antibody used. Mice injected with a high dose (100 #g) 
of rat anti-mouse IgD made both a primary response to rat 
IgG and also a secondary one after challenge with the same 
dose of the same antibody. However, when one tenth of the 
dose was used to prime the mice, they made neither a pri- 
mary or a secondary response, although challenge was again 
made with the high dose (31).  The anti-IgD-peptide  con- 
jugates in our own experiments were used at a dose of 100 
#g.  As noted above,  such a dose of anti-IgD  in mice was 
stimulatory while lower doses induced tolerance. Rats have 
~10x  the body weight of mice and this difference may help 
to explain  the failure of all but one of our anti-IgD-pep- 
tide-treated rats to make an antibody response to mouse IgG. 
However, the single animal that did respond was completely 
protected from EAE after challenge with MBP in CFA, indi- 
cating that a humoral response to mouse IgG was not neces- 
sarily associated with a failure of the protective mechanism. 
Furthermore,  the observations on T cell responses from rats 
pretreated with anti-IgD-peptide conjugates and then chal- 
lenged with MBP in CFA are not compatible with the view 
that T cell nonresponsiveness to MBP or to the encephalito- 
genic peptide thereof was induced by this protocol. In vitro 
stimulation of lymphocytes from nodes draining the site of 
challenge with MBP in CFA showed that  such cells from 
anti-IgD-peptide-pretreated  donors proliferated  as well to 
MBP as those from control rats pretreated with PBS (Fig. 
1). When the encephalitogenic peptide of MBP was used to 
stimulate the cultures,  the results were more variable,  but 
the responses equal in magnitude to those obtained from con- 
trols were compatible with complete protection from EAE. 
Furthermore,  the anti-MBP  antibody titers obtained from 
pretreated rats (Fig. 7) indicate that the anti-IgD-peptide con- 
jugate treatment led to no deficiency of T cell help for anti- 
body synthesis. 
The alternative suggested explanation for the prevention 
of  EAE  by  anti-IgD-peptide  pretreatment,  namely  the 
modification of the cytokine response to MBP by this con- 
jugate, derives from the observations that when nonresting 
B cells serve as APCs,  the T  cells activated in this manner 
synthesize  IL-4 (7-9)  and have,  more broadly,  a Th2-type 
cytokine repertoire (7-9, 32). Because the cytokines I1,-4, IL- 
10, and IL-13 produced by Th2 cells are known to antagonize 
cell-mediated immune responses (11-13, 33-37), it could be 
anticipated that targeting of the encephalitogenic peptide of 
MBP to B cells would induce T cells whose cytokines would 
inhibit EAE (7, 11, 14, 15, 38). Consistent with these pub- 
lished findings,  T cells from pretreated rats differed from those 
of controls. They produced consistently less IFN-3, on acti- 
vation in vitro (Fig.  4) and were much inferior in their ca- 
pacity to transfer EAE to naive recipients (Fig. 2). These two 
observations are compatible since it has been shown previ- 
ously that MBP-specific T  cell lines and clones that induce 
EAE in recipient rats are IFN-3' producers (15,  16, 38) and 
EAE is regarded as a cell-mediated autoimmune disease (2, 
14, 39). In contrast to this apparent deficiency in ceU-mediated 
342  Cytokines  and T Cell Migration in the Pathogenesis of EAE immune responses in T cells from pretreated rats, the mRNA 
levels for IL-4 and IL-13 were ~5-10 times higher than those 
from controls (Fig. 5). As noted, these cytokines are known 
to antagonize cell-mediated immune responses so that these 
observations are consistent with the failure of pretreated rats 
to develop EAE.  The ability of injections of neutralizing 
anti-rat IL-4 mAb to attenuate the protective effect of the 
anti-IgD-peptide pretreatment (Table 2) also indicates a role 
for IL-4 in this protection. However, these findings do not 
account for the diminished cell infiltration into the CNS that 
resulted from the pretreatment unless it can be demonstrated 
that cells with a Th2-type cytokine repertoire, unlike Thl 
cells,  either do not migrate into the noninflamed CNS or 
do not recruit other leukocytes into tissues from the circula- 
tion. Relevant to this interpretation of our data, it has been 
reported that Thl but not Th2 clones mediate delayed-type 
hypersensitivity (40) and that IFN-~r plays an essential role 
in the recruitment of lymphocytes into delayed-type hyper- 
sensitivity lesions (41). 
Combining these published data with the data in this paper 
makes it possible to account for the protective effects of the 
anti-IgD-peptide conjugate and for the histological findings 
in our experiments. We conclude that the conjugate pretreat- 
merit induced a Th2-type T cell response to the encephalitogen 
and that the cells induced in this manner have an intrinsic 
inability to infiltrate the noninflamed CNS. The results also 
suggest that further studies on the expression of adhesion 
molecules on subsets  of T  cells would be valuable. 
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